Early Access — free while we kick the tires
EdgarHawk

Hung David

PRESIDENT AND CEO

Director Officer 10% Owner
2 filings analyzed · 1 company · Latest 2025-06-18

Companies

Company Buys Sells Direction
Nuvation Bio Inc. NUVB 3 0 Net buying

Activity

June 2025
2025-06-18 Nuvation Bio Inc. NUVB
high
Buy
500,000 shares
$893,500
Significance 7/10

NUVB CEO Hung David bought 500,000 shares at $1.79; stock down 53.3% from 52-week high, cluster buy pattern from 4 other insiders in past 14 days

Hung David, President and CEO, purchased 500,000 shares at $1.79 on 2025-06-16, expanding his position from 58.78M to 59.28M shares. The buy occurs with the stock trading 53.3% below its 52-week high of $3.83 and down 22.2% over the past 30 days, while the company remains unprofitable with a net loss of $53.2M in its most recent full fiscal year. Notably, four other insiders have also purchased shares within the past 14 days, creating a cluster buying pattern. David's own cross-ticker track record shows an average 30-day return of +36.7% on his two prior open-market purchases, though his two prior NUVB-specific buys (2025-04-04 and 2025-04-07) have produced 30-day gains of 47.9% and 25.5% respectively, with longer-term outcomes not yet measurable.

April 2025
2025-04-08 Nuvation Bio Inc. NUVB
high
Buy
500,000 shares
$820,220
Significance 6/10

CEO Hung David purchased 500,000 shares (500.0K shares) for $820,220.00 at blended avg $1.64 as stock down 56.7% from 52-week high

President and CEO Hung David executed two separate purchases totaling 500,000 shares for $820,220.00 on April 4–7, 2025, at an average price of $1.64, increasing his holdings to 58.78M shares. This transaction occurs against a backdrop of significant stock deterioration: the current price of $1.66 sits 56.7% below the 52-week high of $3.83, with a 90-day decline of 44.8%. The company remains unprofitable with negative net income of $-41.2M against minimal revenue of $727.0K in the latest quarter, and the broader market cap stands at $558.7M. The CEO's accumulation during a period of sharp price weakness, combined with his substantial pre-existing stake, provides a factual observation of insider capital deployment aligned with depressed valuations, though the company's operational losses and revenue deficit remain material financial concerns.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access